CLINICAL TRIALS PROFILE FOR FENOFIBRATE (MICRONIZED)

All Clinical Trials for Fenofibrate (micronized)

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00309712 ↗	Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study	Completed	Abbott	N/A	2002-08-01	The primary study hypothesis of this study is to determine whether there is a greater percentage of patients achieving a triglyceride level of <200 mg/dL with the combination of simvastatin 20 mg and fenofibrate 160mg than with either simvastatin 20 mg monotherapy or fenofibrate 160mg monotherapy.
NCT00309712 ↗	Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study	Completed	Merck Sharp & Dohme Corp.	N/A	2002-08-01	The primary study hypothesis of this study is to determine whether there is a greater percentage of patients achieving a triglyceride level of <200 mg/dL with the combination of simvastatin 20 mg and fenofibrate 160mg than with either simvastatin 20 mg monotherapy or fenofibrate 160mg monotherapy.
NCT00309712 ↗	Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study	Completed	Intermountain Health Care, Inc.	N/A	2002-08-01	The primary study hypothesis of this study is to determine whether there is a greater percentage of patients achieving a triglyceride level of <200 mg/dL with the combination of simvastatin 20 mg and fenofibrate 160mg than with either simvastatin 20 mg monotherapy or fenofibrate 160mg monotherapy.
NCT00359281 ↗	Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents	Completed	Aegerion Pharmaceuticals, Inc.	Phase 2	2006-03-01	This phase II, open-label research study was conducted in 129 healthy volunteers. Each subject will be given one initial oral dose of one of 7 FDA-approved medications (probe drugs), followed by a 7 day period where subjects receive the study medication AEGR-733 at 10 or 60 mg. On study day 8 subjects will receive the second oral dose of the same probe drug that was given on day 1 and a last dose of AEGR-733 (total of 7 doses).Subjects will return in 1 week for a final safety visit. Each FDA- approved probe drug will be given to ten (10) or fifteen (15) subjects. Safety, pharmacokinetic and pharmacodynamic assessments will be performed.
NCT00422396 ↗	Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis	Completed	Abbott	N/A	2001-01-01	This is a randomized placebo controlled clinical trial designed to investigate the effects of micronized fenofibrate on fasting and postprandial lipoproteins, oxidized fatty acids and lipoproteins, inflammatory mediators and thrombotic factors among hypertriglyceridemic individuals with two or more other characteristics of the metabolic syndrome.

Clinical Trial Conditions for Fenofibrate (micronized)

Condition Name

Condition Name for Fenofibrate (micronized)
Intervention	Trials
Healthy Male Volunteers	2
Healthy	1
Hypertriglyceridemia With the Metabolic Syndrome	1
Microalbuminuria	1

Condition MeSH

Condition MeSH for Fenofibrate (micronized)
Intervention	Trials
Dyslipidemias	2
Thrombosis	1
Metabolic Syndrome X	1
Metabolic Syndrome	1

Clinical Trial Locations for Fenofibrate (micronized)

Trials by Country

Trials by Country for Fenofibrate (micronized)
Location	Trials
United States	3
Korea, Republic of	2
Greece	1

Trials by US State

Trials by US State for Fenofibrate (micronized)
Location	Trials
Illinois	1
Pennsylvania	1
Utah	1

Clinical Trial Progress for Fenofibrate (micronized)

Clinical Trial Phase

Clinical Trial Phase for Fenofibrate (micronized)
Clinical Trial Phase	Trials
Phase 4	2
Phase 2	1
Phase 1	2

Clinical Trial Status

Clinical Trial Status for Fenofibrate (micronized)
Clinical Trial Phase	Trials
Completed	5
Unknown status	2

Clinical Trial Sponsors for Fenofibrate (micronized)

Sponsor Name

Sponsor Name for Fenofibrate (micronized)
Sponsor	Trials
Hanlim Pharm. Co., Ltd.	2
Abbott	2
Merck Sharp & Dohme Corp.	1

Sponsor Type

Sponsor Type for Fenofibrate (micronized)
Sponsor	Trials
Industry	6
Other	4